New York Rangers Legend Henrik Lundqvist Signs On For ‘Life DisRPted' Campaign [Forbes]
Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (KNSA)
Last kiniksa pharmaceuticals, ltd. - class a ordinary shares earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: Forbes
Getty Images The medical condition that ended Henrik Lundqvist's playing career has set him up to make his next great save. On Oct. 1, Lundqvist announced that he has teamed up with Kiniksa Pharmaceuticals for a campaign called ‘Life DisRPted,' to raise awareness about a condition called recurrent pericarditis, or RP. Inducted into the Hockey Hall of Fame in 2023, Lundqvist enjoyed an elite 15-year NHL career with the New York Rangers. He was named a finalist for the Vezina Trophy five times and won in 2012, as well as taking the Rangers to the Stanley Cup final in 2014. Internationally, Lundqvist backstopped his native Sweden to gold medals at the 2006 Winter Olympics and 2017 IIHF World Championship. He had his number raised to the rafters at Madison Square Garden in 2022. Henrik Lundqvist of the New York Rangers makes a mask save at Madison Square Garden. (Photo by Bruce ... [+] Bennett/Getty Images) Getty Images Throughout his pro career, he was aware of a leaky aorti
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.MarketBeat
- Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue GuidanceGlobeNewswire
- Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx ConferenceGlobeNewswire
KNSA
Earnings
- 10/29/24 - Miss
KNSA
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/12/25 - Form 4
- 2/10/25 - Form 144
- KNSA's page on the SEC website